MaxCyte, Inc. Notice of Full Year Results (7489H)
15 3월 2018 - 4:01PM
UK Regulatory
TIDMMXCT TIDMMXCR
RNS Number : 7489H
MaxCyte, Inc.
15 March 2018
MaxCyte, Inc.
("MaxCyte" or the "Company")
Notice of Full Year Results
Gaithersburg, Maryland - 15 March 2018: MaxCyte (LSE: MXCT,
MXCR), a global cell-based medicines and life sciences company,
will be announcing its full year audited results for the year ended
31 December 2017 on Wednesday 4 April 2018.
Doug Doerfler, Chief Executive Officer, will host a presentation
and live conference call for analysts at 11.00am BST on the day of
the results at the offices of Panmure Gordon, One New Change,
London, EC4M 9AF.
For further information, please contact:
MaxCyte Inc.
Doug Doerfler, Chief Executive
Officer
Ron Holtz, Chief Financial
Officer +1 301 944 1660
Nominated Adviser and Broker
Panmure Gordon
Freddy Crossley (Corporate
Finance)
Ryan McCarthy
Tom Salvesen (Corporate Broking) +44 (0) 20 7886 2500
Financial PR Adviser
Consilium Strategic Communications
Mary-Jane Elliott +44 (0)203 709 5700
Chris Welsh maxcyte@consilium-comms.com
Suki Virji
About MaxCyte
MaxCyte (LSE: MXCT, MXCR) is a global cell-based medicines and
life sciences company applying its patented cell engineering
technology to help patients with high unmet medical needs in a
broad range of conditions. MaxCyte is developing novel CARMA
therapies for its own pipeline. CARMA is MaxCyte's mRNA-based
proprietary platform for autologous cell therapy. In addition,
through its core business, the Company leverages its Flow
Electroporation(R) technology to enable its partners across the
biopharmaceutical industry to advance the development of innovative
medicines, particularly in cell therapy, including gene editing and
immuno-oncology. The Company has placed its cutting-edge flow
electroporation instruments worldwide, including with nine of the
top ten global biopharmaceutical companies, and has more than 50
partnered programme licenses in cell therapy including more than 20
licensed for clinical use in cell therapy. With its robust delivery
technology, MaxCyte helps its partners to unlock the full potential
of their products.
For more information, visit http://www.maxcyte.com/.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NORJIMATMBBBBBP
(END) Dow Jones Newswires
March 15, 2018 03:01 ET (07:01 GMT)
Maxcyte (LSE:MXCT)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Maxcyte (LSE:MXCT)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024